Maurer, Marcus http://orcid.org/0000-0002-4121-481X
Magerl, Markus http://orcid.org/0000-0001-9218-5468
Funding for this research was provided by:
Projekt DEAL
Article History
Accepted: 13 January 2021
First Online: 3 February 2021
Compliance with Ethical Standards
:
: Marcus Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Alnylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Celldex, Centogene, CSL Behring, Dyax, FAES, Genentech, GIInnovation, Innate Pharma, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Pharming, Pharvaris, Roche, Sanofi/Regeneron, Shire/Takeda, Third HarmonicBio, UCB, and Uriach. Markus Magerl is or recently was a speaker and/or advisor for and/or has received research funding from BioCryst, CSL Behring, Kalvista, Novartis, Octapharma, Pharming, Sanofi/Regeneron, Shire/Takeda.